5 August 2021, Seppo Kopsala, CEO / Lars Lindqvist, CFO

Result presentation Q2/2021

Highlights

Highlights Q2-2021

Very strong growth: Revenue increased 55%. Software growth was 21% and

  1. Devices 124% against a weak Covid-19 affected comparison period
  2. Sinopharm-Phoebus: cooperation started in Q1 and continues, and it is currently driving our growth in China
    Favourable megatrends continue: supports our decision to continue the
  3. investments in expanding the sales channels, focusing on clinical research, and developing and launching new products

Focus areas

China:

  • The Sinopharm-Phoebus deliveries continued to increase
  • Training of the regional sales organizations have started
  • Currently it is hard to forecast revenue for H2-2021 in China and the long-term potential can only be assessed after 12-18 months

USA:

  • Direct sales performing well and as planned
  • Distribution network expansion continues
  • The clinical trials with the aim to the FDA approval for Aurora AEYE, a handheld camera with autonomous AI for retinal screening, are progressing as planned

COVID-19 Coronavirus

  • Delta variant spreading; vaccinations progressing
  • What does it mean to Optomed:
    • The Software segment is performing well due to the recurring revenue model
    • The travel restrictions continue to slow down the global screening solution sales
    • Device segment's traditional marketing and sales affected by travel restrictions
    • Possible lockdowns may affect negatively on especially on Devices segment's sales

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Optomed plc published this content on 05 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2021 07:15:03 UTC.